Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Thioredoxin reductase plays an critical role in lung cancer patients, in vitro study showed
that, ethaselen, specific inhibitor of thioredoxin reductase, could inhibit lung cancer cell
growth and induce apoptosis. In China, phase 1 clinical trials of ethaselen showed that 1200
mg dose ethaselen could be well tolerated, in pre-clinical study we found that, approximately
50% non-small cell lung cancers harbored high thioredoxin reductase expression(IHC result ++
or +++), phase 1a/b of ethaselen had finished in 2008, the result showed that 1200mg
ethaselen per day was safety and tolerated by Chinese malignant tumor patients.In
pre-clinical research, our group found that, elevated of thioredoxin reductase activity was
associated with the expression of thioredoxin reductase tested by immunohistochemistry, which
means high expression of this enzyme may be a favourite predicted factor of ethaselen, the
specific inhibitor of thioredoxin reductase.